Now showing items 1-3 of 3

  • Ree, Anne Hansen; Russnes, Hege Elisabeth Giercksky; Heinrich, Daniel; Dueland, Svein; Pedersen, Kjetil Boye; Nygaard, Vigdis; Silwal-Pandit, Laxmi; Østrup, Olga; Hovig, Eivind; Nygaard, Vegard; Rødland, Einar Andreas; Nakken, Sigve; Øien, Janne T; Johansen, Christin; Bergheim, Inger; Skarpeteig, Veronica; Sathermugathevan, Menaka; Sauer, Torill; Lund-Iversen, Marius; Beiske, Klaus; Nasser, Salah; Julsrud, Lars; Reisse, Claudius; Ruud, Espen Asak; Flørenes, Vivi Ann; Hagene, Kirsten T; Aas, Eline; Lurås, Hilde; Soriano, Siv Johnsen; Geitvik, Gry Aarum; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Mælandsmo, Gunhild; Flatmark, Kjersti (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
    Objective Through the conduct of an individual-based intervention study, the main purpose of this project was to build and evaluate the required infrastructure that may enable routine practice of precision cancer medicine ...
  • Ree, Anne Hansen; Nygaard, Vigdis; Pedersen, Kjetil Boye; Heinrich, Daniel; Dueland, Svein; Bergheim, Inger Riise; Johansen, Christin; Beiske, Klaus; Negård, Anne; Lund-Iversen, Marius; Nygaard, Vegard; Hovig, Eivind; Nakken, Sigve; Nasser, Salah; Julsrud, Lars; Reisse, Claudius; Ruud, Espen Asak; Kristensen, Vessela N.; Flørenes, Vivi Ann; Geitvik, Gry; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Russnes, Hege Elisabeth Giercksky; Mælandsmo, Gunhild Mari; Flatmark, Kjersti (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
    Background: In precision cancer medicine, the challenge is to prioritize DNA driver events, account for resistance markers, and procure sufficient information for treatment that maintains patient safety. The MetAction ...
  • Öjlert, Åsa Kristine; Halvorsen, Anita; Nebdal, Daniel; Lund-Iversen, Marius; Solberg, Steinar; Brustugun, Odd Terje; Lingjærde, Ole Christian; Helland, Åslaug (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    The impact of the tumor immune microenvironment on overall survival in non‐small cell lung cancer (NSCLC) has been studied, but there is little information on its relevance for risk of relapse after surgery. Understanding ...